Navigation Links
Dr. Richard Rosenbloom Resumes Services To The Quigley Corporation's Pharma Subsidiary
Date:7/10/2009

DOYLESTOWN, Pa., July 10 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that Dr. Richard Rosenbloom has resumed providing services to the Company's Quigley Pharma subsidiary. Dr. Rosenbloom had been temporarily suspended from the Company in late May, 2009.

Ted Karkus, Chairman and interim CEO of the Company, said, "We are pleased to have Dr. Rosenbloom again serving our Pharma subsidiary and helping in the development and evaluation of our new products. The Company has long acknowledged Dr. Rosenbloom's importance to the continued development of our Pharma product lines. The Company is continuing to look into the issues that resulted in Dr. Rosenbloom's prior suspension, and we are pleased to have this very talented and experienced individual back in his laboratory while these matters are under review."

Dr. Richard Rosenbloom joined the Company in 2000 as Executive Medical Director and Chairman of its Medical Advisory Board. In 2001, he helped establish Quigley Pharma with the goal of developing naturally derived compounds and botanical prescription drugs addressing therapeutic areas that have not been successfully covered by major pharmaceutical companies.

Dr. Rosenbloom has served as Director of Medical Affairs for Asta Medica Pharmaceuticals, directing international clinical drug trials in diabetes complications, pain and cancer, and as Medical Director of Biotrax Clinical Research, a contract research organization (CRO) in diabetes complications and rheumatoid arthritis.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    CONTACT:

    Ted Karkus                    Media                    Investor Relations
    Chairman of the Board, CEO    Karen Pineman            Carl Hymans
    The Quigley Corporation       G.S. Schwartz & Co.      G.S. Schwartz & Co.
    215.345.0919                  212.725.4500             212.725.4500
                                  kpineman@schwartz.com    carlh@schwartz.com


'/>"/>
SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Richard Greco Joins Mediware Board
2. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
3. Healthcare Veteran Richard Findlay Joins Diamond Management & Technology Consultants as Partner
4. Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission
5. Richard L. Antoine to Retire as P&Gs Global HR Officer
6. Reed Smith to Merge with Richards Butler Hong Kong
7. GSA confers 2007 Richard Kalish Innovative Publication Award to USCs Mather
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Richard Drouant Joins OrthoSynetics(TM) as Graphic Designer
10. Los Angeles Daily Journal Names Richardson & Patel Verdict Top in the State of California for 2007
11. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology: